title: Hemocoagulase agkistrodon-induced anaphylactic shock: A case report and literature review.
abstract: Hemocoagulase agkistrodon for injection is the national first-class new drug of China with good hemostatic function and safety for capillary hemorrhage in abdominal incision of surgical patients. Adverse drug reactions (ADRs) to hemocoagulase agkistrodon are rarely reported. In this paper, we describe a case of a 41-year-old woman who developed anaphylactic shock attributed to hemocoagulase agkistrodon before colon cancer surgery. Based on the Naranjo ADR probability score, a "probable" cause and effect relationship existed for this case. Although the cause of anaphylactic reaction (hemocoagulase or excipient) and exact mechanism of hemocoagulase agkistrodon-induced anaphylactic reaction are unknown, attention should be drawn to potential ADRs in clinical use.
authors.forename: Yan-Yan
authors.initials: YY
authors.lastname: Xu
authors.forename: Xu-Hui
authors.initials: XH
authors.lastname: Ma
authors.forename: Shao-Jun
authors.initials: SJ
authors.lastname: Zhang
mesh_terms: D000328:Adult; D017836:Agkistrodon; D000707:Anaphylaxis / Q000209:etiology*; D000818:Animals; D012103:Batroxobin / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007267:Injections
chemical_list: D012103:Batroxobin